Affiliated Sites
  • Clinicians Network Payer Bioinformatics
Be The Match

Javascript disabled. This site requires JavaScript How to enable JavaScript.

You are using an outdated browser. Please upgrade your browser to improve your experience.

Close

NMDP

Be The Match
  • About Us
  • Services & Support
  • Cart
  • Transplant Indications and Outcomes
    • HLA Today
    • Disease-Specific Indications and Outcomes
      • AML - Adult
      • AML - Pediatric
      • ALL - Adult
      • ALL - Pediatric
      • Myelodysplastic Syndromes (MDS)
      • CML
      • CLL
      • NHL
      • Hodgkin Lymphoma
      • Multiple Myeloma
      • Severe Aplastic Anemia & Marrow Failure
      • Sickle Cell Disease
      • Immune Deficiency Diseases
      • Inherited Metabolic Disorders
      • Thalassemia
      • Other Diseases
      • Myeloproliferative Neoplasms
    • Additional Outcomes
      • Unrelated vs. Sibling Donor Outcomes
      • Older Patient Outcomes
      • Timing Impact on Outcomes
    • Eligibility
    • Referral Timing Guidelines
    • Order Kits
    • HLA Typing for Family Members
  • Transplant Therapy and Donor Matching
    • Cell Sources
    • HLA Typing and Matching
    • Donor or Cord Blood Search Process
      • Likelihood of Finding a Match
      • Preliminary Search Request
    • Jason Carter Clinical Trials Program
  • Post-Transplant Care
    • Early Complications
    • Vaccinations
    • Long-Term Care Guidelines
      • Pediatric Considerations
    • Chronic GVHD
      • Skin
      • Nails
      • Scalp and Body Hair
      • Eyes
      • Mouth
      • Lungs
      • Muscles, Fascia, Joints
      • Hematopoietic & Immune
      • GI Tract
      • Liver
      • Genitalia
      • Other
    • Post-Transplant Guidelines
  • Medical Education & Research
    • Browse News
      • Results of Study on COVID-19 Vaccine Response in Hematopoietic Cell Transplant Patients Published in eClinicalMedicine
    • Browse Research
    • Education Catalog
      • HLA and Search Strategy Resources
      • GVHD Interactive Provider Network Virtual Learning Series
    • Materials Catalog
    • HCT Presentation Slides
    • About Our Research
    • Transplant Enews
  • Resources
    • Patient Resources
    • Financial Resources
    • Obstetrician Resources
    • Technique Videos
    • Umbilical Cord Blood Collection Training for Public Donation
    • Local Provider Partnership Program
  • HLA Today
  • Disease-Specific Indications and Outcomes
  • Additional Outcomes
  • Eligibility
  • Referral Timing Guidelines
  • Order Kits
  • HLA Typing for Family Members

Disease-Specific Indications and Outcomes

  • AML - Adult
  • AML - Pediatric
  • ALL - Adult
  • ALL - Pediatric
  • Myelodysplastic Syndromes (MDS)
  • CML
  • CLL
  • NHL
  • Hodgkin Lymphoma
  • Multiple Myeloma
  • Severe Aplastic Anemia & Marrow Failure
  • Sickle Cell Disease
  • Immune Deficiency Diseases
  • Inherited Metabolic Disorders
  • Thalassemia
  • Other Diseases
  • Myeloproliferative Neoplasms
  • Transplant Indications and Outcomes
  • Disease-Specific Indications and Outcomes
  • Email
  • Print This Page

Related Resources

  • Unrelated Donor Outcomes (PDF)
  • HCT Referral Timing Guidelines 
  • Patient Eligibility
  • All Outcomes and Statistics Slides

 

Patient Resources

  • Transplant Basics Booklet
  • Transplant Basics Videos
  • Transplant Outcomes and Treatment Decisions

Disease-Specific HCT Indications and Outcomes Data

New outcomes data and research has defined which patients can benefit from hematopoietic cell transplant (HCT) and when this therapy is best applied.  HCT offers a potential cure for blood cancers, such as leukemia and lymphoma, and other life-threatening diseases.  

HCT Data Trends  

Overall volume trends and indications for transplantation are presented in the figures below. The data show autologous and allogeneic HCT volume, age trends and disease indications for transplant. 

Data in this section have been prepared by the CIBMTR® (Center for International Blood and Marrow Transplant Research®). The CIBMTR is a research collaboration between the National Marrow Donor Program® (NMDP)/Be The Match® and the Medical College of Wisconsin. 

Figure 1. Volume Trend of Allogeneic and Autologous HCT   slide3_The-US-Summary-Slides-2022-v2---web-version

Download slide

Figure 2. Volume of Allogeneic HCT by Disease Type  

slide53_The-US-Summary-Slides-2022-v2---web-version 1

Download slide

Figure 3. Age Trend of Allogeneic HCT  

slide45_The-US-Summary-Slides-2022-v2---web-version

Download slide

Figure 4. Age Trend of Autologous HCT  

slide46_The-US-Summary-Slides-2022-v2---web-version

Download slide

HCT Consultation Timing Guidelines  

The National Marrow Donor Program® (NMDP)/Be The Match® and the American Society for Transplantation and Cellular Therapy (ASTCT) have jointly developed guidelines for transplant consultation and referral timing based on disease characteristics. [1] The National Comprehensive Cancer Network Clinical Practice Guidelines (NCCN Guidelines®) were consulted when developing these guidelines and are a valuable tool for determining risk stratification. [2] 

Our guidelines highlight disease categories that include patients at risk for disease progression and who should be referred for a consultation for autologous or allogeneic transplantation.

View the complete HCT Consultation Timing Guidelines

Outcomes and Indications by Disease  

Access current research, outcomes and HCT Consultation Timing Guidelines below to support your clinical decision-making. 

Leukemia and Myelodysplasia  

  • Acute Myeloid Leukemia (AML) - Adult
  • Acute Myeloid Leukemia (AML) - Pediatric
  • Acute Lymphoblastic Leukemia (ALL) - Adult  
  • Acute Lymphoblastic Leukemia (ALL) - Pediatric 
  • Myelodysplastic Syndromes (MDS)
  • Chronic Myeloid Leukemia (CML) 
  • Chronic Lymphocytic Leukemia (CLL)

Lymphomas and Multiple Myeloma 

  • Non-Hodgkin Lymphoma (NHL)
  • Hodgkin Lymphoma (HL) 
  • Multiple Myeloma (MM) and Other Plasma Cell Disorders  

Non-Malignant Disorders and Other Diseases  

  • Severe Aplastic Anemia (SAA) and Other Marrow Failure Syndromes
  • Sickle Cell Disease (SCD)
  • Thalassemia
  • Immune Deficiency Diseases
  • Inherited Metabolic Disorders   
  • Myeloproliferative Neoplasms (MPN)  
  • Other Diseases

Clinical Trials Search and Support 

The NMDP/Be The Match offers the Be The Match® Jason Carter Clinical Trials Search and Support (CTSS) program, which can provide clinical trial navigation to your patients. The CTSS Program was created to help people with blood cancers or blood disorders and their families find and join clinical trials.

For more information, visit Clinical Trials Search and Support.  

References 

  1. NMDP/Be The Match and ASTCT Recommended Timing for Transplant Consultation. Download (PDF)
  2. National Comprehensive Cancer Network. NCCN Guidelines. 2023. Access
    • Email
    • Print This Page

    Slides may be downloaded and used without permission for one-time presentation or personal use.  For publication, use in print or web, or repeated presentations, please submit a Copyright Request Form.

    Keep In Touch

    • Contact Us
    • Transplant Enews

    Our Websites

    • Be The Match
    • Be The Match Mexico
    • Be The Match BioTherapies
    • CIBMTR
    • Jason Carter Clinical Trials Search
    National Marrow Donor Program —
    Entrusted and under contract to operate the C.W. Bill Young Cell Transplantation Program, including Be The Match Registry®.
    Copyright © 1996-2023 National Marrow Donor Program. All Rights Reserved. Terms of Use | Privacy Policy | Trademark & Copyright